

PHARMACEUTICAL 2022

ANAPTYSBIO INC

Rank 11 of 466









RealRate

PHARMACEUTICAL 2022



ANAPTYSBIO INC Rank 11 of 466

The relative strengths and weaknesses of ANAPTYSBIO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANAPTYSBIO INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 58% points. The greatest weakness of ANAPTYSBIO INC is the variable Intangible Assets, reducing the Economic Capital Ratio by 1.4% points.

The company's Economic Capital Ratio, given in the ranking table, is 310%, being 232% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	553,876
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,099
Liabilities, Non-Current	0
Other Assets	86,911
Other Compr. Net Income	-418
Other Expenses	0
Other Liabilities	0
Other Net Income	-982
Other Revenues	63,175
Property and Equipment	2,283
Research and Development	98,496
Selling, General and Administrative Expense	21,493

Output Variable	Value in 1000 USD
Assets	643,070
Liabilities	16,099
Expenses	119,989
Revenues	63,175
Stockholders Equity	626,971
Net Income	-57,796
Comprehensive Net Income	-58,005
Economic Capital Ratio	310%

